Clinical outcomes of tucidinostat-based therapy after prior CDK4/6 inhibitor progression in hormone receptor-positive heavily pretreated metastatic breast cancer-Reference-Cited by-同舟云学术

Clinical outcomes of tucidinostat-based therapy after prior CDK4/6 inhibitor progression in hormone receptor-positive heavily pretreated metastatic breast cancer

Published:2022-12 Issue: Volume:66 Page:255-261
ISSN:0960-9776
Container-title:The Breast
language:en
Short-container-title:The Breast

Author:

Zhou Jinmei,Wu Xuexue,Zhang Huiqiang,Wang Xiaobo,Yuan Yang,Zhang Shaohua,Jiang Zefei,Wang Tao^ORCID

Funder

National Natural Science Foundation of China

Beijing Municipal Natural Science Foundation

Publisher

Elsevier BV

Subject

General Medicine,Surgery

Reference27 articles.

1. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020;Cao;Chin Med J,2021

2. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5);Cardoso;Ann Oncol,2020

3. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

4. Palbociclib and letrozole in advanced breast cancer;Finn;N Engl J Med,2016

5. Ribociclib as first-line therapy for HR-positive, advanced breast cancer;Hortobagyi;N Engl J Med,2016

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Epigenetic Modulations in Breast Cancer: An Emerging Paradigm in Therapeutic Implications;Frontiers in Bioscience-Landmark;2024-08-19

2. The Effects of Anlotinib Combined with Chemotherapy following Progression on Cyclin‐Dependent Kinase 4/6 Inhibitor in Hormone Receptor‐Positive Metastatic Breast Cancer;The Breast Journal;2024-01

3. The Evolving Pathways of the Efficacy of and Resistance to CDK4/6 Inhibitors in Breast Cancer;Cancers;2023-10-02

4. Navigating next-generation HR+/HER2− metastatic breast cancer therapies: a critical commentary on abemaciclib vs. tucidinostat after palbociclib progression;Translational Breast Cancer Research;2023-10

5. Emerging Role of Epigenetic Modifiers in Breast Cancer Pathogenesis and Therapeutic Response;Cancers;2023-08-07